BPC-157 vs TB-500: A Research Comparison
Two of the most discussed recovery and tissue-repair research peptides, side by side. What each compound is, what each is studied for, how their proposed mechanisms differ, and why researchers describe them as complementary in the Wolverine stack. Research use only.
BPC-157 vs TB-500 at a Glance
BPC-157 and TB-500 are both research peptides studied in tissue-repair contexts, but they are framed around different proposed mechanisms. BPC-157 is a synthetic 15-amino-acid peptide investigated for localised connective-tissue and gut-tissue research. TB-500 is a 7-amino-acid fragment of Thymosin Beta-4 studied for systemic cell migration. Researchers often pair them as the Wolverine stack because the pathways are described as complementary.
This page is general educational information for laboratory and research audiences. Neither BPC-157 nor TB-500 is approved by the TGA for human therapeutic use, and nothing here is medical, legal or dosing advice. All efficacy language is research-framed. These compounds have not been assessed by the TGA for safety, quality or efficacy.
BPC-157 vs TB-500: Side-by-Side Comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Compound type | Synthetic pentadecapeptide | Synthetic peptide fragment |
| Amino acids | 15 (pentadecapeptide) | 7 in the TB-500 fragment (Ac-LKKTETQ); the full Thymosin Beta-4 parent protein has 43 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Acetylated LKKTETQ (residues 17-23 of Thymosin Beta-4) |
| Approx. molecular weight | ~1,419 Da | Short fragment; full Thymosin Beta-4 is ~4,921-4,982 Da |
| Origin | Partial sequence of a body-protection compound found in human gastric juice | Active actin-binding region of Thymosin Beta-4, a naturally occurring protein in nearly all cells |
| Primary research focus | Angiogenesis, growth-factor signalling, localised tendon, ligament and gut-tissue repair research | G-actin regulation and cell migration, framed as more systemic tissue remodelling |
| Research framing | Often described as more localised | Often described as more systemic |
| Common pairing | Paired with TB-500 in the Wolverine stack | Paired with BPC-157 in the Wolverine stack |
| AU regulatory status | Schedule 4, TGA-unapproved, research use only | Schedule 4, TGA-unapproved, research use only |
| WADA status | Prohibited (S0), banned at all times | Prohibited (S0), banned at all times |
What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide, meaning it is a chain of 15 amino acids. Its name stands for Body Protection Compound 157, because it corresponds to a partial sequence of a body-protection compound identified in human gastric juice. The peptide was first described in scientific literature in 1993 by Sikiric and colleagues, and it is produced today through solid-phase peptide synthesis.
Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1,419 Da. One characteristic noted in the research literature is unusual stability in gastric juice. Most peptides degrade rapidly in acidic gastrointestinal environments, which makes this stability a frequently cited point of interest in preclinical study designs.
BPC-157 is among the most-studied peptides in the tissue-repair space, with a substantial preclinical research literature. It is investigated for tendon, ligament, muscle and gastrointestinal tissue research. Mechanistic studies describe angiogenesis, which is the formation of new blood vessels including VEGFR2 signalling, alongside collagen synthesis support, growth-factor signalling and nitric-oxide modulation. Human clinical evidence remains limited, so all of this is best understood as what the compound is studied for rather than any established effect.
BPC-157 research highlights
- Synthetic 15-amino-acid peptide derived from a gastric-juice body-protection compound
- Investigated in preclinical models for tendon, ligament, muscle and gut-tissue repair
- Mechanistic research describes angiogenesis, growth-factor signalling and collagen support
- Most-studied peptide in the tissue-repair category, though human data is limited
What Is TB-500?
TB-500 is where precision matters, because vendor pages routinely get this wrong. TB-500 commonly refers to a synthetic 7-amino-acid peptide fragment with the acetylated sequence Ac-LKKTETQ. This fragment corresponds to the active actin-binding region, residues 17 to 23, of the full-length protein Thymosin Beta-4.
Thymosin Beta-4 itself is a 43-amino-acid naturally occurring polypeptide, with a molecular weight of roughly 4,921 to 4,982 Da, found in nearly all cells. Many sources conflate the two and incorrectly label TB-500 as a 43-amino-acid peptide. To be accurate: TB-500 is the short LKKTETQ fragment, while Thymosin Beta-4 is the full 43-amino-acid parent protein.
TB-500 and Thymosin Beta-4 are studied for their role in actin regulation. The molecule binds and sequesters monomeric G-actin, which regulates the polymerisation and depolymerisation of actin. That process is central to cell migration, cytoskeletal remodelling and wound-healing research, and it is why TB-500 is often framed as having more systemic, body-wide activity. One caveat worth noting: the strongest human trial data in this area uses full-length Thymosin Beta-4, for example a topical eye-drop formulation, rather than the injected TB-500 fragment.
If a page tells you TB-500 has 43 amino acids, treat it with caution. The 43-amino-acid count belongs to full-length Thymosin Beta-4. The TB-500 fragment itself is the 7-residue Ac-LKKTETQ sequence. Getting this right is one of the clearest signals of an accurate source.
How They Differ: Localised vs Systemic Research Framing
The clearest way to separate these two peptides is by the pathways their research centres on. The mechanisms are described as complementary and largely non-overlapping, which is the foundation of the entire comparison.
BPC-157 research centres on growth-factor receptor signalling, angiogenesis and focal-adhesion or connective-tissue support. This is often framed as more localised tissue repair, with study interest concentrated around tendon, ligament and gastrointestinal contexts. TB-500 research centres on G-actin sequestration and cell migration, which is often framed as more systemic and body-wide. The two are described in the literature as complementary pathways that converge on tissue repair from different directions.
The mechanistic split, at a glance
- BPC-157: localised framing, growth-factor and angiogenesis-led research, tendon, ligament and gut focus
- TB-500: systemic framing, actin-regulation and cell-migration-led research, broader tissue-remodelling focus
- Together: distinct, non-overlapping pathways that researchers describe as complementary
Which Is Better, BPC-157 or TB-500?
This is the question most searchers arrive with, and the honest research answer is that it is not a contest between two interchangeable options. The two peptides are studied around different mechanisms, so framing one as universally superior misrepresents the research. We cannot and do not recommend either for any individual, body or injury, because that would cross into medical advice.
What the literature does support is a mechanistic distinction. If a research interest is localised connective-tissue and gut signalling, BPC-157 is the compound that body of work centres on. If the interest is systemic cell migration and broader tissue remodelling, TB-500 and Thymosin Beta-4 are where that research sits. Because the pathways are described as complementary rather than competing, researchers frequently study them together rather than choosing one.
The most useful answer to BPC-157 vs TB-500 is not a winner. It is the recognition that the two are studied along complementary, non-overlapping pathways, which is precisely why they are so often paired.
The Wolverine Stack: Why Researchers Pair Them
The Wolverine stack is the common name for combining BPC-157 and TB-500 in research and recovery contexts. The pairing rationale, framed strictly as research interest, is complementary mechanisms. BPC-157 contributes localised growth-factor and angiogenesis-led activity, while TB-500 contributes systemic cell-migration activity. Because these pathways are described as non-overlapping, the combination is the natural reason researchers cite for studying them side by side.
In the literature, the pairing is most often discussed in the context of tendon, ligament and muscle-tear research. Achilles, patellar and rotator-cuff models are frequently cited examples. We do not provide dosing, reconstitution, frequency or stacking protocols, and the Wolverine stack should be understood here as a research-pairing concept only, not a usage instruction.
For researchers who want both compounds in a single, documented package, NovaPeptides supplies a complete Wolverine-style research kit pairing BPC-157 and TB-500. Every kit ships with a third-party Janoshik Certificate of Analysis for independent lab verification, alongside Australian shipping. Enquiries are handled directly over WhatsApp, with no cart, prices or purchase claims attached. The kit is supplied for research use only.
Third-party Janoshik Certificate of Analysis (COA)
Legal and Regulatory Status in Australia
This section is general information only and is not legal or medical advice. In Australia, BPC-157 was specifically scheduled by the Therapeutic Goods Administration as a Schedule 4, prescription-only medicine substance. Australia was reportedly the first country to specifically schedule BPC-157, and the TGA cited a high risk of misuse in athletic, fitness, wellness and anti-ageing markets. TB-500 and Thymosin Beta-4 are also Schedule 4 in Australia.
Neither BPC-157 nor TB-500 is approved by the TGA for human therapeutic use. Both are supplied for research use only and have not been assessed by the TGA for safety, quality or efficacy. We describe this situation neutrally and factually. We do not advise on how to obtain these compounds without a prescription, how to import them, or how to navigate around scheduling.
Both BPC-157 and TB-500, along with Thymosin Beta-4, appear on the WADA Prohibited List under category S0, non-approved substances. They are prohibited at all times, classified as non-specified substances, and there is no Therapeutic Use Exemption pathway. BPC-157 was added to the WADA list in 2022, and real anti-doping sanctions, including multi-year bans, have occurred.
For a fuller breakdown of the research-use-only framework and how NovaPeptides handles compliance, see the dedicated research-use-only and sourcing guides linked below.
Frequently asked questions
What is the difference between BPC-157 and TB-500?+
BPC-157 is a synthetic 15-amino-acid peptide derived from a body-protection compound in gastric juice, and its research centres on localised connective-tissue and gut-tissue repair, angiogenesis and growth-factor signalling. TB-500 is a synthetic 7-amino-acid fragment of Thymosin Beta-4, and its research centres on G-actin regulation and cell migration, which is framed as more systemic. The two are studied along complementary, non-overlapping pathways.
Is BPC-157 or TB-500 better?+
Neither is universally better, because they are studied around different mechanisms. BPC-157 research is framed as more localised, while TB-500 research is framed as more systemic. Because the pathways are described as complementary rather than competing, researchers often study them together rather than choosing one. We do not recommend either for any individual or injury, as that would be medical advice.
Can you stack BPC-157 and TB-500?+
Combining BPC-157 and TB-500 is commonly referred to as the Wolverine stack in research contexts. The rationale researchers cite is complementary mechanisms: BPC-157's localised growth-factor and angiogenesis activity alongside TB-500's systemic cell-migration activity. It is most often discussed in tendon, ligament and muscle research. We describe this as a research-pairing concept only and do not provide dosing or stacking protocols.
How many amino acids does TB-500 have?+
The TB-500 fragment is the acetylated 7-amino-acid sequence Ac-LKKTETQ, corresponding to residues 17 to 23 of Thymosin Beta-4. The full-length Thymosin Beta-4 parent protein has 43 amino acids. Many sources incorrectly label TB-500 itself as 43 amino acids, which conflates the short fragment with the full protein.
Are BPC-157 and TB-500 legal in Australia?+
In Australia, both BPC-157 and TB-500 are Schedule 4, prescription-only medicine substances under the Poisons Standard, and neither is approved by the TGA for human therapeutic use. Both are supplied for research use only and have not been assessed by the TGA for safety, quality or efficacy. This is general information, not legal advice.
Are BPC-157 and TB-500 banned in sport?+
Yes. Both BPC-157 and TB-500, along with Thymosin Beta-4, are on the WADA Prohibited List under category S0, non-approved substances. They are prohibited at all times, classified as non-specified substances, and there is no Therapeutic Use Exemption pathway. BPC-157 was added to the WADA list in 2022.
Does NovaPeptides supply BPC-157 and TB-500 together?+
NovaPeptides supplies a complete Wolverine-style research kit that pairs BPC-157 and TB-500, with a third-party Janoshik Certificate of Analysis for independent lab verification and Australian shipping. Everything is supplied for research use only, with enquiries handled over WhatsApp. No purchase, dosing or outcome claims are attached.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp